Accelerating the Development of pan-TB Regimens

Successfully treating TB can be complex and challenging. New regimens with little to no drug resistance – known as pan-TB regimens – create a simpler and more effective treatment pathway for all people diagnosed with TB.

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is the first collaboration of philanthropic, non-profit and private-sector organizations that aims to accelerate the identification of promising pan-TB regimens and conduct research through phase 2b/2c clinical trials. These pan-TB regimens will be designed to have improved safety and tolerability, a shorter duration, and simpler to use than existing treatment options.


Preclinical study data now accessible courtesy of the Critical Path Institute 

Data from the PAN-TB Collaboration’s 2020-2023 pharmacokinetic and relapsing mouse model (RMM) studies are now available through the Critical Path Institute Data Archive platform. These preclinical studies evaluated the combination pharmacokinetics and the combination efficacy of novel four-drug combinations of seven priority anti-TB drugs and drug candidates: Bedaquiline (B), Pretomanid (Pa), Sutezolid (Sut), GSK286 (286), GSK830 (830), Delamanid (Del) and Quabodepistat (Q) (formerly OPC-167832 or OPC). 

 Study data currently available: 

  • Pharmacokinetic evaluations of novel 4-drug anti-TB drug combinations in mice with multiple dosing frequencies to inform RMM studies, in addition to evaluations of comparator drug combinations
  • Relapsing mouse model evaluations of novel 4-drug anti-TB drug combinations

 All available data is mapped to the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data (SEND).

Researchers can request access to the data by following the link below. All access requests are reviewed by a committee and may take up to four weeks to process. New data will be added as they become available. 

Request Access

PAN-TB Collaboration Announces the Start of a Phase 2 Clinical Trial to Evaluate Two Novel Tuberculosis Treatment Regimens

Public-private partnership launched a first-of-its-kind phase 2b/c trial to evaluate two novel tuberculosis drug regimens with the potential to treat all forms of active pulmonary TB

Read more

Phase 2b/c Clinical Trial Update

The Phase 2b/c trial was launched in South Africa in July 2023. Sites in South Africa and the Philippines are actively screening and enrolling participants. As of June 28, 2024, 90 participants have been enrolled.


Overview of Partners

The members of the PAN-TB collaboration have committed to leveraging their unique assets, resources and scientific expertise to advance the development of novel regimens.

PAN-TB Priority Candidates

Registered product for multidrug-resistant TB, Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, New Chemical Entity for drug-sensitive TB, TB Alliance
Registered product, Otsuka Pharmaceutical Co., Ltd
Registered product, TB Alliance
New Chemical Entity, TB Alliance Medicine Patent Pool, Bill & Melinda Gates Medical Research Institute
New Chemical Entity, GSK
New Chemical Entity, GSK
New Chemical Entity, Otsuka Pharmaceutical Co., Ltd
New Chemical Entity, TB Alliance